Current as of December 10, 2023
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
- DISEASE CHARACTERISTICS:
- Histologically confirmed superficial transitional cell carcinoma of the bladder pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required. No metastatic disease or muscle invasion.
- Clinically useful pretreatment bladder function required.
- No significant prostatic obstructive symptoms associated with impaired or incomplete bladder emptying.
- No active urinary tract infection.
- PRIOR/CONCURRENT THERAPY:
- At least 1 course of prior standard intravesical therapy required.
- At least 4 weeks since intravesical treatment, with resolution of any local or systemic toxicity.
- PATIENT CHARACTERISTICS:
- Age: 18 and over.
- Performance status: ECOG 0 or 1.
- WBC at least 3,300;
- Hemoglobin at least 10 g/dL.
- Bilirubin no greater than 1.5 mg/dL;
- AST and ALT no greater than 2 times normal.
- Renal: Creatinine no greater than 1.5 mg/dL.
- Medically able to undergo cystoscopy.
- No pregnant women.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients